Treatment for Hepatocellular carcinoma.

AN OPEN LABELLED RCT STUDY TO ASSESS THE COMBINED EFFICACY OF NABBK KASHAYA, PANCHAGAVYA GHRITA MATRA BASTI, CHULIKA VATI WITH ASHWAGANDHA ARKA ANUPANA IN IMPROVING BLOOD PARAMETERS AND QUALITY OF LIFE OF PATIENTS OF HEPATOCELLULAR CARCINOMA [ NICHAYA GULMA ] - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058760

Enrollment

Registered

2023-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1] Patients diagnosed with hepatocellular carcinoma. 2] Patients of either sex aged between 20 and 70 years. 3] Patients posted for chemotherapy and radiotherapy. 4] Patients who have dropped from chemotherapy and radiotherapy. 5] Patients not willing for any modern anti cancer treatment. 6] Patients who will sign the informed consent form. 7] Patients fit for the administration of matra basti.

Exclusion criteria

Exclusion criteria: 1] Patients who are unconscious or in the stage of coma, MODS. 2] Patients with oncological emergencies and other malignancies. 3] Patients with proved HCC but with metastasis. 4] Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
To improve quality of life of patients of Hepatocellular carcinoma.Timepoint: 7 weeks, 6 days	—

Secondary

Measure	Time frame
To improve blood parameters Duration- 9 weeks, 6 daysTimepoint: 9 weeks, 6 days	—

Countries

India

Contacts

Public ContactDr Vindhya keshav

Taranath Government Ayurvedic Medical College and Hospital, Bellary

drfareedabegumshaikh@gmail.com9886478611

Outcome results